Meridian Bioscience Inc. (VIVO)
(Delayed Data from NSDQ)
$11.51 USD
-0.48 (-4.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.51 USD
-0.48 (-4.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Abbott's (ABT) Q1 Earnings and Revenues Exceed Estimates
by Zacks Equity Research
Within Adult Nutrition, Abbott (ABT) gains from the strong performance of Ensure and Glucerna brands in Q1.
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Robust global demand for Oncotype DX and increased Cologuard orders are likely to have driven Exact Sciences' (EXAS) Q1 performance.
Edwards Lifesciences (EW) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) first-quarter performance.
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
by Zacks Equity Research
Excluding COVID testing sales, Abbott's (ABT) worldwide Diagnostic sales are expected to have demonstrated strong growth in Q1 on the continuous rollout of Alinity, Abbott's suite of diagnostic instruments.
Quest Diagnostics (DGX) Q1 Earnings to Grow on Base Business
by Zacks Equity Research
Quest Diagnostics (DGX) is expected to report a strong first half of Q1 with a growing number of cases and then a dull second half on gradual stabilization in testing demand.
Zacks.com featured highlights include Meridian Bioscience, Innoviva, OP Bancorp and United Fire Group
by Zacks Equity Research
Meridian Bioscience, Innoviva, OP Bancorp and United Fire Group are part of Screen of the Week article.
What Makes Meridian Bioscience (VIVO) a Good Fit for "Trend Investing"
by Zacks Equity Research
Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Bet on These 4 Low-Beta Stocks to Combat Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), OP Bancorp (OPBK) and United Fire Group (UFCS) are well poised to gain.
New Strong Buy Stocks for March 25th
by Zacks Equity Research
CLH, VIVO, EOG, TGT, and COLM have been added to the Zacks Rank #1 (Strong Buy) List on March 25, 2022.
Zacks.com featured highlights include Meridian Bioscience, OP Bancorp, ICU Medical and Pangaea Logistics Solutions
by Zacks Equity Research
Meridian Bioscience, OP Bancorp, ICU Medical and Pangaea Logistics Solutions have been highlighted in this Screen of the Week article.
Buy These 4 Low-Beta Stocks to Combat the Choppy Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), OP Bancorp (OPBK), ICU Medical (ICUI) and Pangaea Logistics (PANL) are well poised to gain.
New Strong Buy Stocks for March 22nd
by Zacks Equity Research
AA, HLI, RUSHA, COLM, and VIVO have been added to the Zacks Rank #1 (Strong Buy) List on March 22, 2022.
Meridian Bioscience and NeuroPace have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Meridian Bioscience and NeuroPace have been highlighted as Zacks Bull and Bear of the Day.
Bull of the Day: Meridian Bioscience (VIVO)
by Kevin Cook
Beat-and-raise quarter launches shares and estimates as growth in diagnostics returns
Zacks.com featured highlights include Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences
by Zacks Equity Research
Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences are included in this blog.
Sail Through the Choppy Market With These 4 Low-Beta Stocks
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.
Will Meridian Bioscience (VIVO) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Meridian Bioscience (VIVO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Meridian Bioscience (VIVO) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 40% and 19.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Meridian Bioscience (VIVO) Q1 Earnings Expected to Decline
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience (VIVO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience (VIVO) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of -29.03% and -13.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Danaos Corp, Boyd Gaming, Costamare, Meridian Bioscience and Magnolia Oil & Gas
by Zacks Equity Research
Zacks.com featured highlights include: Danaos Corp, Boyd Gaming, Costamare, Meridian Bioscience and Magnolia Oil & Gas
4 Profitable Stocks to Boost Returns Using Net Income Ratio
by Nitish Marwah
DAC, BYD, CMRE, VIVO, and MGY qualified the screen for the net income ratio for the day.
Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Meridian Bioscience (VIVO) closed at $22.05, marking a +1.61% move from the previous day.